Cellosaurus logo
expasy logo
Due to maintenance work, this service will be unavailable on Monday between 06:00 until 06:30 CEST. Apologies for the inconvenience.

Cellosaurus PC-3 (CVCL_0035)

[Text version]
Cell line name PC-3
Synonyms PC3; PC.3
Accession CVCL_0035
Resource Identification Initiative To cite this cell line use: PC-3 (RRID:CVCL_0035)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: JFCR39 cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Part of: NCI-60 cancer cell line panel.
Population: Caucasian.
Doubling time: 25.34 +- 0.02 hours (PubMed=32968452); 25 hours (ATCC=CRL-7934); 40 +- 10 hours (CLS=300312); ~50 hours (DSMZ=ACC-465); 27.1 hours (NCI-DTP=PC-3); ~25 hours (PBCF).
Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep antibody staining analysis.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: Glycoproteome analysis by proteomics.
Omics: GPI-anchored proteins analysis by proteomics.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Secretome proteome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Caution: There seem to be two distinct cell lines which were assigned NCBI_Iran catalog number C427.
Derived from site: Metastatic; Bone; UBERON=UBERON_0002481.
Sequence variations
  • Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (PubMed=1873816; PubMed=8104329; PubMed=17088437; Cosmic-CLP=905934; DepMap=ACH-000090).
HLA typing Source: PubMed=15748285
Class I
HLA-AA*01:01:01,24:02:01
HLA-BB*13:02,55:01
HLA-CC*01,06
Class II
HLA-DPDPB1*04:01
HLA-DQDQB1*02:02,06:03
HLA-DRDRB1*07:01,13:01:01

Source: PubMed=25960936
Class I
HLA-AA*01:01,24:01
HLA-BB*13:02,55:01
HLA-CC*01:02,06:02

Source: PubMed=26589293
Class I
HLA-AA*01:01,24:02
HLA-BB*13:02,55:01
HLA-CC*01:02,06:02
Class II
HLA-DRDRB1*13:01,13:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.41
Native American0
East Asian, North0.52
East Asian, South0
South Asian1.19
European, North65.73
European, South32.14
Disease Prostate carcinoma (NCIt: C4863)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_L211 (1-LN)CVCL_C6Y9 (Abcam PC-3 AATF KO)CVCL_C6YA (Abcam PC-3 ABCB1 KO)
CVCL_C6YB (Abcam PC-3 ABL1 KO)CVCL_C6YC (Abcam PC-3 ADGRG1 KO)CVCL_C6YD (Abcam PC-3 AGTR1 KO)
CVCL_C6YE (Abcam PC-3 AHR KO)CVCL_C6YF (Abcam PC-3 AIM2 KO)CVCL_C6YG (Abcam PC-3 ALCAM KO)
CVCL_C6YH (Abcam PC-3 ALKBH1 KO)CVCL_C6YI (Abcam PC-3 ALYREF KO)CVCL_C6YJ (Abcam PC-3 APOBEC3B KO)
CVCL_C6YK (Abcam PC-3 ASAH1 KO)CVCL_C6YL (Abcam PC-3 ATF5 KO)CVCL_C6YM (Abcam PC-3 ATG3 KO)
CVCL_C6YN (Abcam PC-3 ATG9A KO)CVCL_C6YP (Abcam PC-3 BAK1 KO)CVCL_C6YQ (Abcam PC-3 BMPR2 KO)
CVCL_C6YR (Abcam PC-3 BRD1 KO)CVCL_C6YS (Abcam PC-3 BRD2 KO)CVCL_C6YT (Abcam PC-3 BRD9 KO)
CVCL_C6YU (Abcam PC-3 BTG1 KO)CVCL_C6YV (Abcam PC-3 BTK KO)CVCL_C6YW (Abcam PC-3 BTRC KO)
CVCL_C6YX (Abcam PC-3 C3 KO)CVCL_C6YY (Abcam PC-3 CASP3 KO)CVCL_C6YZ (Abcam PC-3 CCRL2 KO)
CVCL_C6Z0 (Abcam PC-3 CD36 KO)CVCL_C6Z1 (Abcam PC-3 CD58 KO)CVCL_C6Z2 (Abcam PC-3 CD59 KO)
CVCL_C6Z3 (Abcam PC-3 CD81 KO)CVCL_C6Z4 (Abcam PC-3 CITED2 KO)CVCL_C6Z5 (Abcam PC-3 CLU KO)
CVCL_C6Z6 (Abcam PC-3 CMKLR1 KO)CVCL_C6Z7 (Abcam PC-3 CMTM6 KO)CVCL_C6Z8 (Abcam PC-3 CNR2 KO)
CVCL_C6Z9 (Abcam PC-3 CST3 KO)CVCL_C6ZA (Abcam PC-3 CTSB KO)CVCL_C6ZB (Abcam PC-3 CUL2 KO)
CVCL_C6ZC (Abcam PC-3 CUL3 KO)CVCL_C6ZD (Abcam PC-3 CUL4B KO)CVCL_B0ZD (Abcam PC-3 CXCL8 KO)
CVCL_C6ZE (Abcam PC-3 CXXC1 KO)CVCL_C6ZF (Abcam PC-3 DCP2 KO)CVCL_C6ZG (Abcam PC-3 DLL1 KO)
CVCL_C6ZH (Abcam PC-3 DVL3 KO)CVCL_C6ZI (Abcam PC-3 EGLN1 KO)CVCL_C6ZJ (Abcam PC-3 EHMT2 KO)
CVCL_C6ZK (Abcam PC-3 EIF2AK4 KO)CVCL_C6ZL (Abcam PC-3 ENG KO)CVCL_C6ZM (Abcam PC-3 EPHB4 KO)
CVCL_C6ZN (Abcam PC-3 ERAP1 KO)CVCL_C6ZP (Abcam PC-3 ETS2 KO)CVCL_C6ZQ (Abcam PC-3 EXO1 KO)
CVCL_C6ZR (Abcam PC-3 FABP4 KO)CVCL_C6ZS (Abcam PC-3 FGF23 KO)CVCL_C6ZT (Abcam PC-3 FKBP5 KO)
CVCL_C6ZU (Abcam PC-3 FOXO1 KO)CVCL_C6ZV (Abcam PC-3 FOXO3 KO)CVCL_C6ZW (Abcam PC-3 FST KO)
CVCL_C6ZX (Abcam PC-3 FTL KO)CVCL_C6ZY (Abcam PC-3 FZD7 KO)CVCL_C6ZZ (Abcam PC-3 GAB1 KO)
CVCL_C7A0 (Abcam PC-3 GLB1 KO)CVCL_C7A1 (Abcam PC-3 GPR132 KO)CVCL_C7A2 (Abcam PC-3 GZMA KO)
CVCL_C7A3 (Abcam PC-3 HNF1B KO)CVCL_C7A4 (Abcam PC-3 HSPG2 KO)CVCL_C7A5 (Abcam PC-3 ID2 KO)
CVCL_C7A6 (Abcam PC-3 IL17RB KO)CVCL_C7A7 (Abcam PC-3 ITPR3 KO)CVCL_C7A8 (Abcam PC-3 JAG1 KO)
CVCL_C7A9 (Abcam PC-3 JMJD6 KO)CVCL_C7AA (Abcam PC-3 KAT7 KO)CVCL_C7AB (Abcam PC-3 KDM1B KO)
CVCL_C7AC (Abcam PC-3 KDM6B KO)CVCL_C7AD (Abcam PC-3 KPNA2 KO)CVCL_C7AE (Abcam PC-3 LAIR1 KO)
CVCL_C7AF (Abcam PC-3 LAMP2 KO)CVCL_C7AG (Abcam PC-3 LDHA KO)CVCL_C7AH (Abcam PC-3 LGR6 KO)
CVCL_C7AI (Abcam PC-3 LMNB1 KO)CVCL_C7AJ (Abcam PC-3 MAGEA3 KO)CVCL_C7AK (Abcam PC-3 MAP2K3 KO)
CVCL_C7AL (Abcam PC-3 MAP3K3 KO)CVCL_C7AM (Abcam PC-3 MAPK7 KO)CVCL_C7AN (Abcam PC-3 MBD1 KO)
CVCL_C7AP (Abcam PC-3 MBD3 KO)CVCL_C7AQ (Abcam PC-3 MMP13 KO)CVCL_C7AR (Abcam PC-3 MMP8 KO)
CVCL_C7AS (Abcam PC-3 MTA3 KO)CVCL_C7AT (Abcam PC-3 NBR1 KO)CVCL_C7AU (Abcam PC-3 NCR3LG1 KO)
CVCL_C7AV (Abcam PC-3 NFKB1 KO)CVCL_C7AW (Abcam PC-3 NLRC4 KO)CVCL_C7AX (Abcam PC-3 NOTCH3 KO)
CVCL_C7AY (Abcam PC-3 NOTCH4 KO)CVCL_C7AZ (Abcam PC-3 NQO1 KO)CVCL_C7B0 (Abcam PC-3 NR1H4 KO)
CVCL_C7B1 (Abcam PC-3 NR3C2 KO)CVCL_C7B2 (Abcam PC-3 PDCD1LG2 KO)CVCL_C7B3 (Abcam PC-3 PHF8 KO)
CVCL_C7B4 (Abcam PC-3 PIK3CA KO)CVCL_C7B5 (Abcam PC-3 PIK3CD KO)CVCL_C7B6 (Abcam PC-3 PIK3R4 KO)
CVCL_C7B7 (Abcam PC-3 PLA2G4A KO)CVCL_C7B8 (Abcam PC-3 PLAU KO)CVCL_C7B9 (Abcam PC-3 PLCB3 KO)
CVCL_C7BA (Abcam PC-3 PLCG1 KO)CVCL_C7BB (Abcam PC-3 PRMT7 KO)CVCL_C7BC (Abcam PC-3 PSEN1 KO)
CVCL_C7BD (Abcam PC-3 PTGER4 KO)CVCL_C7BE (Abcam PC-3 PTGES2 KO)CVCL_C7BF (Abcam PC-3 PTK2 KO)
CVCL_C7BG (Abcam PC-3 PTP4A3 KO)CVCL_C7BH (Abcam PC-3 PTPN12 KO)CVCL_C7BI (Abcam PC-3 PUS1 KO)
CVCL_C7BJ (Abcam PC-3 RAC2 KO)CVCL_C7BK (Abcam PC-3 RING1 KO)CVCL_C7BL (Abcam PC-3 ROCK2 KO)
CVCL_C7BM (Abcam PC-3 ROR2 KO)CVCL_C7BN (Abcam PC-3 RUNX2 KO)CVCL_C7BP (Abcam PC-3 RYBP KO)
CVCL_C7BQ (Abcam PC-3 SCARB1 KO)CVCL_C7BR (Abcam PC-3 SDC4 KO)CVCL_C7BS (Abcam PC-3 SETD2 KO)
CVCL_C7BT (Abcam PC-3 SLFN11 KO)CVCL_C7BU (Abcam PC-3 SMARCAL1 KO)CVCL_C7BV (Abcam PC-3 SMARCC2 KO)
CVCL_C7BW (Abcam PC-3 SMARCE1 KO)CVCL_C7BX (Abcam PC-3 SMURF1 KO)CVCL_C7BY (Abcam PC-3 SMYD2 KO)
CVCL_C7BZ (Abcam PC-3 SMYD3 KO)CVCL_C7C0 (Abcam PC-3 SOCS3 KO)CVCL_C7C1 (Abcam PC-3 SRF KO)
CVCL_C7C2 (Abcam PC-3 SRPK1 KO)CVCL_C7C3 (Abcam PC-3 STAT4 KO)CVCL_C7C4 (Abcam PC-3 STAT5A KO)
CVCL_C7C5 (Abcam PC-3 STK4 KO)CVCL_C7C6 (Abcam PC-3 SUV39H1 KO)CVCL_C7C7 (Abcam PC-3 SUZ12 KO)
CVCL_C7C8 (Abcam PC-3 TAPBP KO)CVCL_C7C9 (Abcam PC-3 TBK1 KO)CVCL_C7CA (Abcam PC-3 TBP KO)
CVCL_C7CB (Abcam PC-3 TCF7L2 KO)CVCL_C7CC (Abcam PC-3 TFDP1 KO)CVCL_C7CD (Abcam PC-3 THBS1 KO)
CVCL_C7CE (Abcam PC-3 TIMP3 KO)CVCL_C7CF (Abcam PC-3 TLN1 KO)CVCL_C7CG (Abcam PC-3 TNFRSF10B KO)
CVCL_C7CH (Abcam PC-3 TNFRSF1B KO)CVCL_C7CI (Abcam PC-3 TP73 KO)CVCL_C7CJ (Abcam PC-3 TRADD KO)
CVCL_C7CK (Abcam PC-3 TRAF2 KO)CVCL_C7CL (Abcam PC-3 TRMT2A KO)CVCL_C7CM (Abcam PC-3 TWIST1 KO)
CVCL_C7CN (Abcam PC-3 TWIST2 KO)CVCL_C7CP (Abcam PC-3 U2AF1 KO)CVCL_C7CQ (Abcam PC-3 UBA1 KO)
CVCL_C7CR (Abcam PC-3 UBE2D2 KO)CVCL_C7CS (Abcam PC-3 UCHL5 KO)CVCL_C7CT (Abcam PC-3 ULBP2 KO)
CVCL_C7CU (Abcam PC-3 ULBP3 KO)CVCL_C7CV (Abcam PC-3 UVRAG KO)CVCL_C7CW (Abcam PC-3 VCAN KO)
CVCL_C7CX (Abcam PC-3 WDR77 KO)CVCL_C7CY (Abcam PC-3 WNT11 KO)CVCL_C7CZ (Abcam PC-3 YTHDC2 KO)
CVCL_C7D0 (Abcam PC-3 YTHDF1 KO)CVCL_C7D1 (Abcam PC-3 YTHDF3 KO)CVCL_C7D2 (Abcam PC-3 YY1 KO)
CVCL_C7D3 (Abcam PC-3 ZEB2 KO)CVCL_4735 (ALVA-101)CVCL_4737 (ALVA-31)
CVCL_4734 (ALVA-41)CVCL_4736 (ALVA-55)CVCL_4738 (DuPro-1)
CVCL_5989 (JHU-019)CVCL_YJ90 (LINTERNA PC-3)CVCL_4868 (MPC-3-10)
CVCL_D3N6 (PC-3 9-7-11)CVCL_4Y40 (PC-3 D12)CVCL_4Y41 (PC-3 D8)
CVCL_6E88 (PC-3 MC)CVCL_6E89 (PC-3 MK)CVCL_6E90 (PC-3 ML)
CVCL_6E91 (PC-3 MR)CVCL_4877 (PC-3-1A)CVCL_C3HH (PC-3-AR)
CVCL_XD72 (PC-3-Cas9-576)CVCL_XD73 (PC-3-Cas9-577)CVCL_XD74 (PC-3-Cas9-578)
CVCL_XD75 (PC-3-Cas9-579)CVCL_J265 (PC-3-Luc)CVCL_A4BV (PC-3-Luc2)
CVCL_5J26 (PC-3-luc2)CVCL_5J29 (PC-3-luc2-GFP)CVCL_C0QS (PC-3-R)
CVCL_5J08 (PC-3-Red-FLuc)CVCL_5J09 (PC-3-Red-FLuc-GFP)CVCL_ZX05 (PC-3-TxR)
CVCL_A2FD (PC-3/DTX)CVCL_M060 (PC-3/nKR)CVCL_B289 (PC-3H)
CVCL_9555 (PC-3M)CVCL_4886 (PC-3N)CVCL_RS45 (PC-3rVCR20)
CVCL_RS41 (PC-3rYM155_20nM)CVCL_0482 (PC-3U)CVCL_M124 (PC-5 [Human prostate carcinoma])
CVCL_X641 (PC-J)CVCL_D5K8 (PC3-eGFP-Neo)CVCL_D5K9 (PC3-eGFP-Neo/Fluc-Puro)
CVCL_B0CB (PC3-epi)CVCL_D5K6 (PC3-Fluc-Neo/iRFP-Puro)CVCL_D5K7 (PC3-Fluc-Puro)
CVCL_D5ZR (PC3-neo)CVCL_WM76 (PC3-R-caba)CVCL_D5ZS (PC3-STEAP-1)
CVCL_C3M5 (PC3/DX)CVCL_D689 (PC3B1)CVCL_B7P9 (PC3PR)
CVCL_C169 (PCI-03)CVCL_4778 (PPC-1)CVCL_YJ69 (VAMPIRO PC-3)
Sex of cell Male
Age at sampling 62Y
Category Cancer cell line
STR profile Source(s): AddexBio=C0019002/61; ATCC=CRL-1435; CCRID; CLS=300312; Cosmic-CLP=905934; DOI=10.4172/2157-7145.S2-005; DSMZ=ACC-465; ECACC=90112714; Technion Genomics Center BCF; JCRB=JCRB9110; KCLB=21435; PubMed=11416159; PubMed=14518029; PubMed=17254797; PubMed=19372543; PubMed=25877200; RCB=RCB2145; TKG=TKG 0600

Markers:
AmelogeninX
CSF1PO11
D1S165612,16
D2S44110,11
D2S133818,20 (ATCC=CRL-1435; CCRID; DOI=10.4172/2157-7145.S2-005; Technion Genomics Center BCF; PubMed=19372543)
20 (DSMZ=ACC-465)
D3S135816
D5S81813 (AddexBio=C0019002/61; ATCC=CRL-1435; CCRID; CLS=300312; Cosmic-CLP=905934; DOI=10.4172/2157-7145.S2-005; DSMZ=ACC-465; ECACC=90112714; KCLB=21435; PubMed=14518029; PubMed=17254797; PubMed=19372543; PubMed=25877200; RCB=RCB2145; TKG=TKG 0600)
13,14 (Technion Genomics Center BCF)
D7S8208 (PubMed=17254797; TKG=TKG 0600)
8,11 (AddexBio=C0019002/61; ATCC=CRL-1435; CCRID; CLS=300312; Cosmic-CLP=905934; DOI=10.4172/2157-7145.S2-005; DSMZ=ACC-465; ECACC=90112714; Technion Genomics Center BCF; JCRB=JCRB9110; KCLB=21435; PubMed=14518029; PubMed=19372543; PubMed=25877200; RCB=RCB2145)
D8S117913
D10S124816
D12S39121
D13S31711
D16S53911
D18S5113,14 (PubMed=17254797)
14,15 (ATCC=CRL-1435; CCRID; CLS=300312; DOI=10.4172/2157-7145.S2-005; DSMZ=ACC-465; Technion Genomics Center BCF; PubMed=11416159; PubMed=14518029; PubMed=19372543; PubMed=25877200)
D19S43314
D21S1129,31 (PubMed=17254797)
29,31.2 (ATCC=CRL-1435; CCRID; CLS=300312; DOI=10.4172/2157-7145.S2-005; DSMZ=ACC-465; Technion Genomics Center BCF; PubMed=11416159; PubMed=14518029; PubMed=19372543; PubMed=25877200)
D22S104515
FGA24
Penta D9
Penta E10,17
TH016,7
TPOX8,9
vWA17

Run an STR similarity search on this cell line
Web pages https://en.wikipedia.org/wiki/PC3
https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
https://www.atcc.org/en/support/technical-support/faqs/morphology-of-atcc-crl-1435
https://www.synapse.org/#!Synapse:syn31544570
https://strap.nci.nih.gov/celline_detail.php?sample_id=53
https://www.proteinatlas.org/learn/cellines
https://web.archive.org/web/20160328064204/http://capcelllines.ca/details.asp?id=37
https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/p/cell-lines-detail-96.html
https://tcpaportal.org/mclp/
Publications

PubMed=571045
Kaighn M.E., Lechner J.F., Narayan K.S., Jones L.W.
Prostate carcinoma: tissue culture cell lines.
Natl. Cancer Inst. Monogr. 49:17-21(1978)

PubMed=447482
Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W.
Establishment and characterization of a human prostatic carcinoma cell line (PC-3).
Invest. Urol. 17:16-23(1979)

PubMed=6244232
Williams R.D.
Human urologic cancer cell lines.
Invest. Urol. 17:359-363(1980)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3335022
Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)

PubMed=1873816
Isaacs W.B., Carter B.S., Ewing C.M.
Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles.
Cancer Res. 51:4716-4720(1991)

PubMed=8104329; DOI=10.1002/pros.2990230206
Carroll A.G., Voeller H.J., Sugars L., Gelmann E.P.
p53 oncogene mutations in three human prostate cancer cell lines.
Prostate 23:123-134(1993)

PubMed=8687134
Pandalai P.K., Pilat M.J., Yamazaki K., Naik H., Pienta K.J.
The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth.
Anticancer Res. 16:815-820(1996)

PubMed=9018337; DOI=10.1002/(SICI)1097-0045(19970101)30:1<58::AID-PROS9>3.0.CO;2-H
Webber M.M., Bello D., Quader S.T.A.
Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines.
Prostate 30:58-64(1997)

PubMed=9460501; DOI=10.1016/s0165-4608(97)00060-5
Nupponen N.N., Hyytinen E.R., Kallioniemi A.H., Visakorpi T.
Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization.
Cancer Genet. Cytogenet. 101:53-57(1998)

PubMed=9823299
Khan J., Simon R.M., Bittner M., Chen Y.-D., Leighton S.B., Pohida T., Smith P.D., Jiang Y., Gooden G.C., Trent J.M., Meltzer P.S.
Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays.
Cancer Res. 58:5009-5013(1998)

PubMed=10702678; DOI=10.1159/000015432
Pan Y., Kytola S., Farnebo F., Wang N., Lui W.-O., Nupponen N.N., Isola J.J., Visakorpi T., Bergerheim U.S.R., Larsson C.
Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping.
Cytogenet. Cell Genet. 87:225-232(1999)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=10754530; DOI=10.1002/(SICI)1097-0045(20000501)43:2<144::AID-PROS9>3.0.CO;2-H
Suzuki Y., Kondo Y., Himeno S., Nemoto K., Akimoto M., Imura N.
Role of antioxidant systems in human androgen-independent prostate cancer cells.
Prostate 43:144-149(2000)

PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H
Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.
Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Mol. Carcinog. 28:236-246(2000)

PubMed=11135431; DOI=10.1002/1098-2264(2000)9999:9999<::AID-GCC1076>3.0.CO;2-E
Aurich-Costa J., Vannier A., Gregoire E., Nowak F., Cherif D.
IPM-FISH, a new M-FISH approach using IRS-PCR painting probes: application to the analysis of seven human prostate cell lines.
Genes Chromosomes Cancer 30:143-160(2001)

PubMed=11172901; DOI=10.1016/S0165-4608(00)00339-3
Strefford J.C., Lillington D.M., Young B.D., Oliver R.T.D.
The use of multicolor fluorescence technologies in the characterization of prostate carcinoma cell lines: a comparison of multiplex fluorescence in situ hybridization and spectral karyotyping data.
Cancer Genet. Cytogenet. 124:112-121(2001)

PubMed=11304728; DOI=10.1002/pros.1045
van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.
Widely used prostate carcinoma cell lines share common origins.
Prostate 47:36-51(2001)

PubMed=11414198; DOI=10.1007/s004320000207
Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J.
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=11416159; DOI=10.1073/pnas.121616198
Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Short tandem repeat profiling provides an international reference standard for human cell lines.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=12606952; DOI=10.1038/sj.onc.1206247
Clark J., Edwards S., Feber A., Flohr P., John M., Giddings I., Crossland S., Stratton M.R., Wooster R., Campbell C., Cooper C.S.
Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays.
Oncogene 22:1247-1252(2003)

PubMed=12725112; DOI=10.1385/1-59259-372-0:21
Russell P.J., Kingsley E.A.
Human prostate cancer cell lines.
Methods Mol. Med. 81:21-39(2003)

PubMed=14518029; DOI=10.1002/pros.10290
van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.
Molecular characterization of human prostate carcinoma cell lines.
Prostate 57:205-225(2003)

CLPUB00698
van Bokhoven A.
Models for prostate cancer. Molecular characterization and critical appraisal of human prostate carcinoma cell lines.
Thesis PhD (2004), Katholieke Universiteit Nijmegen, Netherlands

PubMed=15486987; DOI=10.1002/pros.20158
Zhao H.-J., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R., Brooks J.D.
Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.
Prostate 63:187-197(2005)

PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11.1-11.8(2005)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001
Azari S., Ahmadi N., Jeddi-Tehrani M., Shokri F.
Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.
Biologicals 35:195-202(2007)

PubMed=17440963; DOI=10.1002/pros.20581
Takeda M., Mizokami A., Mamiya K., Li Y.-Q., Zhang J., Keller E.T., Namiki M.
The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
Prostate 67:955-967(2007)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

DOI=10.4172/2157-7145.S2-005
Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M., Hart R.P., Furtado M.R.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
J. Forensic Res. 2 Suppl. 2:5-5(2011)

PubMed=21432867; DOI=10.1002/pros.21383
Tai S., Sun Y., Squires J.M., Zhang H., Oh W.K., Liang C.-Z., Huang J.-T.
PC3 is a cell line characteristic of prostatic small cell carcinoma.
Prostate 71:1668-1679(2011)

PubMed=22068913; DOI=10.1073/pnas.1111840108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22275356; DOI=10.1074/jbc.M111.302547
Lynch T.P., Ferrer C.M., Jackson S.R., Shahriari K.S., Vosseller K., Reginato M.J.
Critical role of O-linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis.
J. Biol. Chem. 287:11070-11081(2012)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017
Kong D.-X., Yamori T.
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22347499; DOI=10.1371/journal.pone.0031628
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23671654; DOI=10.1371/journal.pone.0063056
Lu Y.-H., Soong T.D., Elemento O.
A novel approach for characterizing microsatellite instability in cancer cells.
PLoS ONE 8:E63056-E63056(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20.1-20.13(2013)

PubMed=24504141; DOI=10.3892/ijo.2014.2287
Suetens A., Moreels M., Quintens R., Chiriotti S., Tabury K., Michaux A., Gregoire V., Baatout S.
Carbon ion irradiation of the human prostate cancer cell line PC3: a whole genome microarray study.
Int. J. Oncol. 44:1056-1072(2014)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26256267; DOI=10.1074/mcp.M115.047928
Shah P., Wang X.-C., Yang W.-M., Toghi Eshghi S., Sun S.-S., Hoti N., Chen L.-J., Yang S., Pasay J., Rubin A., Zhang H.
Integrated proteomic and glycoproteomic analyses of prostate cancer cells reveal glycoprotein alteration in protein abundance and glycosylation.
Mol. Cell. Proteomics 14:2753-2763(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.
J. Proteomics 139:77-83(2016)

PubMed=27141528; DOI=10.1016/j.dib.2016.04.001
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.
Data Brief 7:1302-1305(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20.1-20.11(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30244336; DOI=10.1007/s00345-018-2501-6
Samli H., Samli M., Vatansever B., Ardicli S., Aztopal N., Dincel D., Sahin A., Balci F.
Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines.
World J. Urol. 37:1117-1126(2019)

PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132
Hooker S.E. Jr., Woods-Burnham L., Bathina M., Lloyd S., Gorjala P., Mitra R., Nonn L., Kimbro K.S., Kittles R.A.
Genetic ancestry analysis reveals misclassification of commonly used cancer cell lines.
Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31404090; DOI=10.1371/journal.pone.0220807
Jeon J.M., Kwon O.K., Na A.-Y., Sung E.J., Cho I.J., Kim M., Yea S.S., Chun S.Y., Lee J.H., Ha Y.-S., Kwon T.G., Lee S.
Secretome profiling of PC3/nKR cells, a novel highly migrating prostate cancer subline derived from PC3 cells.
PLoS ONE 14:E0220807-E0220807(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=32968452; DOI=10.3892/ol.2020.12093
Liu J., Huang Y.-J., Zhu D.-Y., Dai Y., Liu D., Zhai Y., Liang X.-G., Wu L.-H., Zhao Q.-W.
Establishment and characterization of a docetaxel-resistant human prostate cancer cell line.
Oncol. Lett. 20:230.1-230.7(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) Abcam; ab275472
AddexBio; C0019002/61
ATCC; CRL-1435
ATCC; CRL-7934 - Discontinued
BCRC; 60122
BCRJ; 0269
CCTCC; GDC0095
CLS; 300312
DSMZ; ACC-465
ECACC; 90112714
ICLC; HTL97018
IZSLER; BS TCL 175
JCRB; JCRB9110
KCB; KCB 200725YJ
KCLB; 21435
NCBI_Iran; C427
NCI-DTP; PC-3
RCB; RCB2145
TKG; TKG 0600
Ubigene; YC-C010
Cell line databases/resources CLO; CLO_0008395
CLO; CLO_0051535
MCCL; MCC:0000380
CLDB; cl3881
CLDB; cl3883
cancercelllines; CVCL_0035
CCRID; 1101HUM-PUMC000115
CCRID; 3101HUMSCSP532
CCRID; 3101HUMTCHu158
CCRID; 4201HUM-CCTCC00095
Cell_Model_Passport; SIDM00088
Cosmic-CLP; 905934
DepMap; ACH-000090
DSMZCellDive; ACC-465
FCS-free; 16-2-16-3-6-4
LINCS_HMS; 50454
LINCS_LDP; LCL-1299
Lonza; 125
SKY/M-FISH/CGH; 2799
TOKU-E; 2868
Anatomy/cell type resources BTO; BTO:0001061
Biological sample resources BioSample; SAMN01821588
BioSample; SAMN01821653
BioSample; SAMN01821713
BioSample; SAMN03472063
BioSample; SAMN05292438
BioSample; SAMN10988356
ENCODE; ENCBS420VDY
ENCODE; ENCBS451OVM
ENCODE; ENCBS504WVV
ENCODE; ENCBS596CTT
ENCODE; ENCBS608AAA
ENCODE; ENCBS609AAA
CRISP screens repositories BioGRID_ORCS_Cell_line; 193
Chemistry resources ChEMBL-Cells; CHEMBL3307570
ChEMBL-Targets; CHEMBL390
GDSC; 905934
PharmacoDB; PC3_1248_2019
PubChem_Cell_line; CVCL_0035
Encyclopedic resources Wikidata; Q7118483
Experimental variables resources EFO; EFO_0002074
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM2171
GEO; GSM50225
GEO; GSM50289
GEO; GSM91930
GEO; GSM142459
GEO; GSM142460
GEO; GSM482670
GEO; GSM525804
GEO; GSM595615
GEO; GSM648823
GEO; GSM743480
GEO; GSM750835
GEO; GSM784792
GEO; GSM799370
GEO; GSM799433
GEO; GSM847110
GEO; GSM844675
GEO; GSM844674
GEO; GSM887506
GEO; GSM888588
GEO; GSM1153442
GEO; GSM1178542
GEO; GSM1178543
GEO; GSM1181274
GEO; GSM1181303
GEO; GSM1374817
GEO; GSM1374818
GEO; GSM1670339
GEO; GSM2124647
GEO; GSM4962583
GEO; GSM4962584
GEO; GSM4962585
GEO; GSM4962586
GEO; GSM4962587
GEO; GSM4962588
GEO; GSM4962589
GEO; GSM4962590
GEO; GSM4962591
Medical resources MeSH; D000078722
Polymorphism and mutation databases Cosmic; 688118
Cosmic; 704849
Cosmic; 713868
Cosmic; 719680
Cosmic; 721366
Cosmic; 721556
Cosmic; 755297
Cosmic; 759894
Cosmic; 801350
Cosmic; 809225
Cosmic; 850414
Cosmic; 869157
Cosmic; 873002
Cosmic; 875892
Cosmic; 876396
Cosmic; 897455
Cosmic; 905934
Cosmic; 911997
Cosmic; 918502
Cosmic; 920968
Cosmic; 921048
Cosmic; 922551
Cosmic; 923957
Cosmic; 943175
Cosmic; 948379
Cosmic; 949249
Cosmic; 974299
Cosmic; 1028650
Cosmic; 1028702
Cosmic; 1071477
Cosmic; 1075273
Cosmic; 1092627
Cosmic; 1172628
Cosmic; 1175888
Cosmic; 1188436
Cosmic; 1212489
Cosmic; 1219448
Cosmic; 1305380
Cosmic; 1312367
Cosmic; 1330910
Cosmic; 1436048
Cosmic; 1689714
Cosmic; 1995613
Cosmic; 1998469
Cosmic; 2301588
Cosmic; 2580130
Cosmic; 2585153
Cosmic; 2585230
Cosmic; 2621167
Cosmic; 2651772
Cosmic; 2669172
Cosmic; 2674178
IARC_TP53; 752
IARC_TP53; 21276
LiGeA; CCLE_525
Progenetix; CVCL_0035
Proteomic databases PRIDE; PRD000228
PRIDE; PRD000597
PRIDE; PXD000661
PRIDE; PXD002107
PRIDE; PXD003105
PRIDE; PXD005940
PRIDE; PXD005942
PRIDE; PXD005946
PRIDE; PXD008184
PRIDE; PXD030304
PRIDE; PXD032264
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number48